How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cell-based Humanized Mouse Models Market
- By Model Type: Humanized Immune System (HIS) Models, Humanized Liver Models, Humanized Tumor Models, Humanized Hematopoietic Models, Humanized Neurological Models
- By Cell Source: CD34+ Hematopoietic Stem Cells, Peripheral Blood Mononuclear Cells (PBMCs), Induced Pluripotent Stem Cells (iPSCs), Fetal Liver Cells, Human Tumor Cells
- By Application: Oncology Research, Infectious Disease Modeling, Immunology Studies, Drug Development and Toxicology, Regenerative Medicine Research
- By Mouse Strain: NOD-scid IL2Rgnull (NSG), BALB/c Rag2null IL2Rgnull, NOG (NOD/Shi-scid/IL-2Rγnull), BRG (BALB/c Rag2null IL2Rgnull), SCID-hu
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Humanized Immune System (HIS) Models leads By Model Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 12 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Cell-based Humanized Mouse Models Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Model Type 5
Cell Source 5
Application 5
Mouse Strain 5
Companies profiled
The Jackson Laboratory
Charles River Laboratories International Inc.
Taconic Biosciences Inc.
Envigo RMS
LLC (a part of Inotiv)
Crown Bioscience Inc.
Cyagen Biosciences Inc.
SAGE Labs (a division of BioIVT)
GemPharmatech Co. Ltd.
Shanghai Model Organisms Center Inc.
Harlan Laboratories (now part of Envigo)
Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →The Jackson Laboratory
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Taconic Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Envigo RMS
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →LLC (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Crown Bioscience Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Cyagen Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →SAGE Labs (a division of BioIVT)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GemPharmatech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shanghai Model Organisms Center Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Harlan Laboratories (now part of Envigo)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,165M by 2033 · 8.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Humanized Immune System (HIS) Models57.1
- Humanized Liver Models10.8
- Humanized Tumor Models12.4
- Humanized Hematopoietic Models11.4
- Humanized Neurological Models8.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,700M → $2,987M · 7.3%
Europe$1,185M → $2,292M · 8.6%
Asia Pacific$1,082M → $1,974M · 7.8%
Latin America$669.6M → $1,260M · 8.2%
Middle East and Africa$515.1M → $1,057M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.832026
8.842027
8.842028
8.852029
8.872030
8.872031
8.902032
8.922033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- The Jackson Laboratory11.2
- Charles River Laboratories International Inc.19.2
- Taconic Biosciences Inc.11.7
- Envigo RMS8.5
- LLC (a part of Inotiv)13.7
- Crown Bioscience Inc.7.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Model Type25.5%
Cell Source17.5%
Application14.7%
Mouse Strain42.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.2
- Europe24.0
- Asia Pacific20.6
- Latin America13.2
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| The Jackson Laboratory | 74 | 74 | 84 | 82 | 91 | 95 | 83 |
| Charles River Laboratories International Inc. | 84 | 70 | 70 | 72 | 93 | 81 | 78 |
| Taconic Biosciences Inc. | 84 | 78 | 78 | 84 | 80 | 87 | 82 |
| Envigo RMS | 76 | 80 | 57 | 70 | 63 | 71 | 70 |
| LLC (a part of Inotiv) | 60 | 55 | 63 | 75 | 60 | 57 | 62 |
| Crown Bioscience Inc. | 70 | 64 | 65 | 71 | 67 | 67 | 67 |
| Cyagen Biosciences Inc. | 46 | 53 | 42 | 46 | 61 | 49 | 50 |
| SAGE Labs (a division of BioIVT) | 47 | 37 | 35 | 58 | 36 | 58 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- The Jackson Laboratory
- Charles River Laboratories International Inc.
- Taconic Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| The Jackson Laboratory | ◐ | − | ◐ | ◐ | ✓ | ✓ |
| Charles River Laboratories International Inc. | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Taconic Biosciences Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Envigo RMS | ✓ | ✓ | − | − | ◐ | ✓ |
| LLC (a part of Inotiv) | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Crown Bioscience Inc. | ◐ | − | ◐ | ◐ | ◐ | − |
| Cyagen Biosciences Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| SAGE Labs (a division of BioIVT) | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1The Jackson Laboratory83
2Taconic Biosciences Inc.82
3Charles River Laboratories International Inc.78
4Envigo RMS70
5Crown Bioscience Inc.67
6LLC (a part of Inotiv)62
7Cyagen Biosciences Inc.50
8SAGE Labs (a division of BioIVT)45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
The Jackson LaboratoryCharles River Laboratories International Inc.Taconic Biosciences Inc.
Challenger2
Strong scale, closing on the leaders.
Envigo RMSCrown Bioscience Inc.
Contender1
Focused players with pockets of strength.
LLC (a part of Inotiv)
Niche2
Specialists in a single segment or region.
Cyagen Biosciences Inc.SAGE Labs (a division of BioIVT)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Model Type in North America, then scale across Cell-based Humanized Mouse Models Market — a $94M beachhead inside a $1.49B market.
Beachhead (SOM)$94Mobtainable near-term
Serviceable (SAM)$570Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Humanized Immune System (HIS) Models
Best fit — highest urgency & budget in Model Type.
Economic buyer77 fit
Humanized Liver Models
Strong fit — clear ROI and a fast path to value.
End user68 fit
Humanized Tumor Models
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Model Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cell Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel30%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Model Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell-based Humanized Mouse Models Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified26%
Evaluation14%
Closed-won6%
$16.0KCAC
$61KLTV
3.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cell-based Humanized Mouse Models Market is a durable-growth opportunity — $11.3B by 2033, compounding at 9.5%.
TAM · 2025$5.45Btoday
TAM · 2033$11.3Bforecast
CAGR9.5%2027–2033
Cumulative$72.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$11.3BTotal addressable market
SAM$4.33BServiceable available market
SOM$774MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Model Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Model Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$11.3BLarge & growingTAM by 2033 at 9.5% CAGR
$4.33BServiceable nowreachable with today’s model
$774MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.81BBear6.2% CAGR
$11.3BBase9.5% CAGR
$14.5BBull12.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cell Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cell-based Humanized Mouse Models Market — a $1.40B market by 2033. Plan: grow share from 7.2% to 13.8%.
Market size · 2033$1.40Btotal addressable
Market CAGR11.5%2027–2033
Target share13.8%from 7.2% today
Revenue ambition$193Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.2% | 13.8% | On track |
| Revenue | $106M | $193M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.5% | 45.1% | On track |
| Customer retention | 88.9% | 93.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Model Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cell Source capability
A defensible second engine — invest in Cell Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Model Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cell Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $20M capacity & capability investment
- Greenlight bolt-on M&A in Cell Source
- Authorise North America expansion plan
- Fund R&D program for Model Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cell-based Humanized Mouse Models Market conversation — a $5.35B market you can size, segment and defend in minutes.
Market size · 2033$5.35Btotal opportunity
Growth10.7%CAGR to 2033
Addressable buyers996+accounts in scope
Typical ROI6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Model Type
Goal Grow share in Model Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6×return on cost, year one
< 3 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
The Jackson LaboratoryCharles River Laboratories International Inc.Taconic Biosciences Inc.Envigo RMSLLC (a part of Inotiv)Crown Bioscience Inc.Cyagen Biosciences Inc.SAGE Labs (a division of BioIVT)+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell-based Humanized Mouse Models Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cell-based Humanized Mouse Models Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Ophthalmic Biometers Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportSpinal Electrical Stimulation Devices Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportSkin Stapler Market
Market size, share, segmentation and regional forecast.
$593M market · 2025 base year
View reportGlaucoma Surgical Devices Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportExamination Camera Market
Examination Camera Market is valued at USD 1.88 Billion in 2025 and is expected to reach USD 2.…
$1.9B market · 2025 base year
View reportSlit Lamps Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportAdvanced Animal Ventilator Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportInfusion Pump System Accessories and Software Market
Market size, share, segmentation and regional forecast.
$705M market · 2025 base year
View reportAnti-Fog Dental Mirror Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportUrology Lasers Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportHigh-Frequency Percussive Ventilator Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportNon-resorbable Cranial Fixation Systems Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.